Federal health agencies have ended their recommended pause on the use of Johnson & Johnson’s Janssen coronavirus vaccine.
This comes after a panel of Centers for Disease Control and Prevention advisors voted to resume the one-dose vaccine.
Emergency use authorization, from The Food and Drug Administration for this vaccine now includes a new warning about the “plausible” risk of rare but serious blood clots in adult women under 50.
The vote to recommend resuming use of the Johnson & Johnson vaccine was held Friday, April 23, 2021, by a panel of advisers to the Centers for Disease Control and Prevention The shots are expected to be accompanied by a new warning concerning an increased risk of rare but serious blood clots for adult women under 50.
A federal health official told the panel Friday that vaccinations could resume once the CDC director approves its recommendations and the Food and Drug Administration publishes an update to its emergency use authorization for the vaccine.
A total of three women have died from the clotting disorder after receiving the vaccine. Seven remain hospitalized and five have been released. Most were under the age of 50.
One man was also diagnosed with the same symptoms after receiving the shot in Johnson & Johnson’s clinical trials.
The case numbers are small when compared to the more than 8 million doses that have been given, according to CDC figures released Friday.